Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE + sintilimab + bevacizumab versus partial hepatectomy for technically resectable multiple hepatocellular carcinoma beyond Milan criteria
ChiCTR2400081779Phase 2Not yet recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab and bevacizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoint: Overall survival. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
sintilimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400081779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081779.